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Shiga-like toxin II (SLT-II) was purified to apparent homogeneity from Escherichia coil K-12 strain NM522
containing the cloned toxin genes on recombinant plasmid pEB1. Purification was accomplished by a series of
column chromatography techniques: anion-exchange, chromatofocusing, cation-exchange, and monoclonal
antibody affinity chromatography. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of the
pure toxin showed that SLT-II consisted of A and B subunits with apparent molecular weights of 32,000 and
10,200 + 800, respectively. A band of molecular weight 25,000 was also observed after sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and identified as the Al subunit by Western immunoblot analysis
with toxin-specific monoclonal antibodies (MAbs). The pl of the purified toxin was 5.2. Approximately 1 pg of
pure SLT-ll was a 50% cytotoxic dose for HeLa cells. The toxin was neutralized by polyclonal antibodies and
MAbs to SLT-II, but was not neutralized by polyclonal antibodies or MAbs to SLT-I. Five hybridomas against
SLT-II were produced (BC5 BB12, DC1 EH5, EA5 BA3, ED5 DF3, and GB6 BA4). Culture supernatant fluids
containing MAbs from these hybridomas did not neutralize the cytotoxicity of SLT-I or Shiga toxin. Western
blot analysis showed that two MAbs (MAb DC1 EH5 and MAb GB6 BA4) recognized the A and Al subunits
of SLT-I and three MAbs (MAb BC5 BB12, MAb EA5 BA3, and MAb ED5 DF3) recognized the B subunit
of SLT-II. MAb BC5 BB12 was used to prepare an affinity column for toxin purification.
In 1977 Konowalchuck et al. (12) reported that certain
Escherichia coli strains associated with diarrheal disease
produced a toxin cytotoxic to Vero cell monolayers. How-
ever, it was not until 1983 that E. coli 0157:H7, the causative
agent of hemorrhagic colitis (5, 27, 34), was shown to
produce Vero toxin (VT) (W.M. Johnson, H. Lior, and G. S.
Bezanson, Letter, Lancet i:76, 1983). A previously de-
scribed E. coli Shiga-like toxin (SLT) (23) and VT were
subsequently determined to be the same toxin (A. D.
O'Brien, T. A. Lively, M. E. Chen, S. W. Rothman, and
S. B. Formal, Letter, Lancet i:702-703, 1983). In addition to
hemorrhagic colitis, E. coli strains producing SLT (VT) have
been associated with hemolytic uremic syndrome (HUS) (9;
M. A. Karmali, M. Petric, C. Lim, P. C. Fleming, and B. T.
Steele, Letter, Lancet ii:1299-1300, 1983), the leading cause
of acute renal failure in children. Most recently, E. coli
0157:H7 has been associated with an even more severe renal
disease complicated with neurological symptoms, thrombot-
ic thrombocytopenic purpura (6).
E. coli 0157:H7 strains have been shown to produce two
antigenically distinct toxins, designated VT1 and VT2 (S. M.
Scotland, H. R. Smith, and B. Rowe, Letter, Lancet i:885-
886, 1985) or SLT-I and SLT-II (33). Both toxins are
bacteriophage encoded (24; S. M. Scotland, H. R. Smith,
G. A. Willshaw, and B. Rowe, Letter, Lancet ii:216, 1983).
SLT-I is structurally similar to Shiga toxin from Shigella
dysenteriae type 1 and is neutralized by anti-Shiga toxin
antibodies (19, 21-23). Both SLT-I and Shiga toxin are
cytotoxic to Vero and HeLa cells, enterotoxic for ligated
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rabbit ileal segments, and paralytic-lethal for various labo-
ratory animals (for a review, see reference 20). Based on
nucleotide sequencing and predicted amino acid composi-
tion, SLT-I and Shiga toxin are identical or nearly identical
proteins (4, 11, 31). Although SLT-II and SLT-I are reported
to have similar biological activities (33), SLT-II is not
neutralized by anti-SLT-I or anti-Shiga toxin antibodies.
Conversely, SLT-II neutralizing antibodies do not neutralize
SLT-I or Shiga toxin.
In addition to 0157:H7, E. coli strains of several other
serotypes isolated from persons with HUS or hemorrhagic
colitis produce either SLT-I or SLT-II or both (1, 15). In the
10 outbreaks of hemorrhagic colitis and HUS investigated by
the Centers for Disease Control to date, the presumptive
epidemic strains have been serotype 0157:H7 and have
produced SLT-II alone or SLT-I and SLT-II. Organisms
received at the Centers for Disease Control that produce
SLT-I alone have been recovered from sporadic cases of
diarrhea, hemorrhagic colitis, or HUS. Although SLT-II was
recognized later, the epidemiologic data suggest that SLT-II
is at least as important as SLT-I as a potential virulence
factor (30). To facilitate the development of immunodiagnos-
tic assays and to investigate the role of SLT-II in the
pathogenesis of HUS and hemorrhagic colitis, we needed
pure toxin. We report here the purification of SLT-II and
the production of SLT-II-specific monoclonal antibodies
(MAbs).
MATERIALS AND METHODS
Crude-toxin preparation. E. coli NM522(pEB1) (J. S.
Spika, L. W. Mayer, and F. P. Downes, Abstr. Annu. Meet.
Am. Soc. Microbiol. 1987, B-67, p. 36) was used as the
source of toxin. E. coli NM522(pEB1) contains the cloned
genes for SLT-II on the recombinant plasmid pEB1 (manu-
1926
SLT-II PURIFICATION AND MONOCLONAL ANTIBODY PRODUCTION
script in preparation). Strain NM522(pEB1) was handled in
accordance with the guidelines set forth by the Recombinant
Advisory Committee (Appendix, Fed. Regist. 51:16972,
1986). Since it produced less toxin than S. dysenteriae type
1 60R, all manipulation of strain NM522(pEB1) were per-
formed under P2 containment.
Strain NM522(pEB1) was grown for 16 to 18 h at 37°C in
Penassay broth (Difco Laboratories, Detroit, Mich.) supple-
mented with 35 ,ug of ampicillin per ml. Aliquots of the
overnight growth were spread onto 65 (150 by 15 mm)
Trypticase soy agar plates (BBL Microbiology Systems,
Cockeysville, Md.), each containing 35 p,g of ampicillin per
ml, and incubated overnight at 37°C. The bacterial growth
was gently scraped from the plates at room temperature and
washed twice by centrifugation at 4°C with 0.15 M NaCl.
The bacteria were then suspended in 0.01 M N-2-hydroxy-
ethylpiperazine-N'-2-ethanesulfonic acid (HEPES) buffer
(pH 7.2) and lysed by two passages in a French pressure cell
(American Instruments, Urbana, Ill.) at 20,000 lb/i 2. Bacte-
rial cells and the resulting lysate were kept on ice during the
lysing procedure. To limit the viscosity of the preparation,
RNase and DNase (Sigma Chemical Co., St. Louis, Mo.),
each at 0.1 mg/ml, and 0.001 M MgCl2 were added to the
lysate. The lysate was then centrifuged at 10,000 x g for 1 h
at 4°C. Crude toxin was extracted from the resulting super-
natant fluid by precipitation with 60% saturated ammonium
sulfate at 4°C. The resulting precipitate was collected by
centrifugation, redissolved in approximately 40 ml of dis-
tilled water (28), and dialyzed three times at 4°C against 150
volumes of 0.1 M Tris hydrochloride (pH 6.5).
Anion-exchange chromatography. Manipulations of all
chromatography columns were performed at room tempera-
ture. The dialyzed crude toxin was applied to a 50-ml (1.6 by
25 cm) DEAE-Sepharose CL-6B (Pharmacia, Uppsala, Swe-
den) column equilibrated with 0.1 M Tris hydrochloride (pH
6.5). The column was washed with the equilibration buffer
until the optical density at 280 nm (OD280) of the eluate
returned to base-line levels. The column was developed with
400 ml of a 0 to 0.6 M NaCl gradient in equilibration buffer,
and the OD280 and cytotoxicity of 3-ml fractions were
monitored. Fractions with greater than 104 50% cytotoxic
doses/ml (CD5Jml) were pooled, concentrated to approxi-
mately 20 ml with a stirred-cell Amicon Concentrator
(Amicon Corp., Danvers, Mass.) by using YM10 Diaflo
Ultrafiltration Membrane Filters (Amicon Corp.), and dia-
lyzed (Spectrapor, 6,000- to 8,000-molecular-weight cutoff;
Spectrum Medical Industries, Inc., Los Angeles, Calif.) at
4°C against 300 volumes of 0.025 M histidine hydrochloride
(pH 6.2).
Chromatofocusing chromatography. PBE 94 resin (Phar-
macia) (21 ml) was equilibrated with 0.025 M histidine
hydrochloride (pH 6.2) in a column (1.0 by 26 cm). The
pooled, concentrated material from the anion-exchange col-
umn was applied to the chromatofocusing column, and
Polybuffer 74 (Pharmacia), adjusted to pH 4.0 with 10 N
HCI, was then applied to form a pH gradient between pH 6
and 4. The OD280 and cytotoxicity of 3-ml fractions were
monitored, and fractions with greater than 104 CD50ml were
pooled, concentrated as above, and dialyzed against 150
volumes of 0.2 M citrate buffer (pH 4.0).
Cation-exchange chromatography. The concentrated toxin
preparation from the chromatofocusing column was applied
to a 25-ml CM-Sepharose CL-6B (Pharmacia) column (1.0 by
30 cm) equilibrated with 0.2 M citrate buffer (pH 4.0). The
column was washed with equilibration buffer until the OD280
of 3-ml fractions returned to base-line levels. Toxin was
eluted with a salt gradient (400 ml of 0 to 0.6 M NaCl in
equilibration buffer), and fractions with greater than 105
CD5J/ml were pooled and concentrated as above. The con-
centrate was then dialyzed at 4°C against 150 volumes of 0.01
M phosphate-buffered saline (PBS) (pH 7.2).
Affinity chromatography. MAb BC5 BB12 was purified
from mouse ascitic fluid by protein A chromatography with
an Affi-Gel protein A MAPS II Kit (Bio-Rad Laboratories,
Richmond, Calif.) as specified by the manufacturer. Pure
immunoglobulin G(4 mg) in 0.1 M HEPES buffer (pH 7.5)
was linked to Affi-Gel Active Ester Agarose resin (Bio-Rad
Laboratories) by incubation of the antibody with 5 ml of
resin at 4°C with gentle agitation. After 4 h of incubation,
unbound resin sites were blocked with 0.5 ml of 1.0 M
ethanolamine hydrochloride (pH 8) for 1 h at room temper-
ature. The resin was packed into a column and washed with
PBS to remove unbound antibody and blocking reagent. The
concentrated toxin from the CM-Sepharose column was
applied to the affinity column and incubated overnight at
4°C. The column was then washed with PBS at room
temperature until the OD280 returned to base-line levels, and
the toxin was eluted with approximately 15 ml of 3.5 M
MgCl2. The eluted fractions were dialyzed at 4°C against 200
volumes of PBS to remove MgCl2. The dialyzed affinity-
purified protein was assayed for cytotoxicity and protein
content and used for further characterization of toxin.
MAb production. The antigen used for all immunizations
was a toxoid of partially purified toxin from E. coli
NM522(pEB1). The toxoid was prepared with toxin from the
chromatofocusing column (21 ,ug/ml of protein, 106 CD5Jml)
as previously described (2). On day 1 each of five female
BALB/c mice aged 6 to 8 weeks was injected intraperitone-
ally with 0.1 ml of an emulsion containing equal parts of
toxoid and complete Freund adjuvant (Sigma). Each mouse
was injected intraperitoneally on day 17 with 0.1 ml of an
emulsion containing equal parts of toxoid and incomplete
Freund adjuvant (1:2) (Sigma). Mice were bled from the
orbital plexus on day 31, and the SLT-II-specific neutralizing
titer of the resulting serum was determined. Two mice with
the highest neutralizing titers were boosted intravenously
with 0.1 ml of toxoid without adjuvant on days 50, 51, and
52. On day 54 one mouse was sacrificed and the spleen was
removed.
Fusion of splenocytes and SP2/0 Agl4 myeloma cells was
performed by the method of Zola and Brooks (36). Culture
supernatant fluids were screened for neutralizing antibody
with toxin from the chromatofocusing column. Hybridomas
that produced culture supernatant fluids with neutralizing
antibody titers of 1:25 or greater were subcloned twice by
limiting dilution at 1 and 0.1 cell per well and reassayed for
neutralizing antibody.
MAb subclasses were determined by the immunodiffusion
assay (8) with concentrated monoclonal culture supernatant
fluids and mouse immunoglobulin chain-specific antisera
(Litton Bionetics Laboratory Products, Charleston, S.C.).
Western immunoblot. Affinity-purified toxin was separated
into subunits by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) in a 15% polyacrylamide gel.
The toxin proteins and molecular weight standards were
then transferred electrophoretically from the gel to a nitro-
cellulose membrane (pore size, 0.45 ,m; Trans Blot Transfer
Medium; Bio-Rad Laboratories) at room temperature by
using 100 mA current overnight or 250 mA for 3 h (3).
The protein molecular weight standards were cut from the
nitrocellulose and stained with amido black (0.2%, wt/vol).
The portion of the nitrocellulose containing the toxin protein
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was sliced into strips approximately 5 mm wide and stained
immunochemically to determine the antibody subunit spec-
ificity. Nitrocellulose strips were first blocked with 0.5% (wt/
vol) evaporated milk in PBS for 30 min and then incubated
for 4 h at room temperature with monoclonal culture super-
natants diluted 1:10 in PBS with 0.05% (vol/vol) Tween-20
(PBS-Tween). After being washed three times in 20 ml of
PBS-Tween, the nitrocellulose strips were incubated for 1 h
at room temperature in diluted (1:3,000 in PBS-Tween) goat
anti-mouse antibody conjugated with horseradish peroxidase
(Bio-Rad Laboratories). Immune complexes were visualized
by developing with a freshly prepared solution of 0.5% (wt/
vol) 3,3'-diaminobenzidine tetrahydrochloride dihydrate (Al-
drich Chemical Co., Inc., Milwaukee, Wis.) in 0.003% H202
and PBS (16).
PAGE. In a determination of toxin purity and subunit
structure, samples from individual chromatography fractions
and concentrated pools were mixed with an equal volume of
sample treatment buffer (0.125 M Tris hydrochloride [pH
6.8], 4% SDS, 20% glycerol, 10% 2-mercaptoethanol) and
heated at 100°C for 4 to 10 min. The reduced and denatured
samples were subjected to PAGE on 1.0-mm SDS-15%
polyacrylamide gels as described by Laemmli (13). After
electrophoresis was complete, the gels were silver stairted to
visualize the protein bands (17). Unless otherwise specified,
all gels were silver-stained to visualize the proteins. Concen-
trated toxin from the CM-Sepharose column was mixed at
room temperature with sample treatment buffer without both
2-mercaptoethanol and SDS and electrophoresed under non-
denaturing conditions on a 15% polyacrylamide gel. After
electrophoresis, the gel was cut into 2-mm slices. The
protein in each slice was passively eluted into PBS and
assayed for cytotoxicity.
Protein determination. The protein content of the purifica-
tion pools was monitored at the completion of each step of
purification by using the Pierce BCA Protein Reagent or
Pierce Coomassie Blue G-250 reagent (Pierce Chemical Co.,
Rockford, Ill.) (29) and bovine serum albumin as a standard.
HeLa cell cytotoxicity assays. Cytotoxicity was measured
in 96-well HeLa cell microdilution cultures by the method of
Gentry and Dalrymple (7). The toxin titer was defined as the
reciprocal of the dilution that resulted in death of 50% of the
HeLa cells (CD50). The neutralization assay was performed
by mixing equal volumes of antiserum and toxin, both
diluted in cell culture medium. The toxin-antitoxin mix-
ture was incubated at 37°C for 1 to 4 h, and 0.1 ml of the
mixture was assayed on HeLa cells for residual cytotoxicity
as previously described (7). When titrating antiserum or
monoclonal culture supernatants for neutralizing antibody,
various dilutions of the antibody samples were mixed with a
fixed dilution of toxin containing approximately 10 to 50
CD50. Cytotoxic activity in crude bacterial extracts or puri-
fied toxin preparations was neutralized by mixing various
dilutions of the toxin preparations with a fixed dilution of
antibody capable of neutralizing approximately 200 CD50 of
the homologous toxin. MAb 13C4 (32; kindly supplied by
A. D. O'Brien, Uniformed Services University of the
Health Sciences, Bethesda, Md.) and rabbit anti-SLT-I were
used as the SLT-I-specific antibody. MAb BC5 BB12 and
rabbit anti-SLT-II were used as SLT-II-neutralizing antibod-
ies.
Preparation of rabbit antisera. Polyclonal rabbit antisera
were prepared against SLT-I purified from E. coli 0157:H7
strain 931 as described by O'Brien and LaVeck (22) and
against partially purified SLT-II (CM-Sepharose fraction)
from E. coli NM522(pEB1). Toxoids were prepared from the
purified toxins by treatment with glutaraldehyde as de-
scribed by Brown et al. (2), and portions (20 pLg of protein
per ml) were emulsified with an equal volume of complete
Freund adjuvant (Sigma Chemical Co.). A 1-ml sample of the
emulsion was injected intradermally in multiple sites (20 to
25 sites, approximately 0.05 ml/site) on the clipped backs of
New Zealand albino rabbits. A second injection of the
antigen was given intramuscularly into the thigh muscle 14
days after the first injection. The rabbits were boosted with
an intravenous injection of toxoid (15 pug of protein) 40 days
after the first injection. Volume bleedings were obtained at 5,
7, and 9 days after the booster injection, and the serum
samples from a given rabbit were pooled.
Isoelectric-point determination. The pl of affinity-purified
toxin was determined by using thin-layer electrofocusing
acrylamide gels (PAG-plate; LKB Instruments, Inc., Rock-
ville, Md.). An anode buffer of 1 M phosphoric acid and a
cathode buffer of 1 M sodium hydroxide were used for a pH
range of 3.5 to 9.5. Gels were electrophoresed for 90 min at
50 mA. Iso-gel pl Markers (FMC Corp., Marine Colloids
Div., Rockland, Maine) were used as standards.
RESULTS
Toxin purification. As a source of toxin we used an E. coli
K-12 strain transformed with the recombinant plasmid pEB1
carrying the SLT-II genes from E. coli EDL880 (serotype
0157:H7), which produces both SLT-I and SLT-II. We
chose the transformed strain to avoid contamination of our
toxin preparation with SLT-I and because it produced 100-
fold more SLT-II than the wild-type parent did.
As an initial purification step, the bacterial cell lysate was
precipitated with 60% saturated ammonium sulfate. The
precipitated crude toxin was then subjected to anion-ex-
change (Fig. 1), chromatofocusing (Fig. 2), cation-exchange
(Fig. 3), and monoclonal anti-toxin affinity chromatography.
Using this scheme, we obtained highly purified toxin with a
specific activity of 9.1 x 108 CD5Jmg (Table 1).
In initial attempts to purify the toxin, molecular sieve
chromatography with Bio-Gel P-100 resin (Bio-Rad Labora-
tories) was introduced after chromatofocusing chromatogra-
phy. This technique did not increase the purity or yield of
toxin and was omitted in subsequent experiments. In con-
trast, cation-exchange chromatography proved to be a very
efficient method of purification. Initial attempts to simplify
the procedure by omitting the DEAE and chromatofocusing
chromatography steps were unsuccessful. Crude toxin pre-
cipitated by ammonium sulfate did not bind efficiently to the
CM-Sepharose column. It is possible that contaminants
which would have been removed by the DEAE and chro-
matofocusing columns interfered with the binding of the
toxin to the cation-exchange column.
After CM-Sepharose chromatography, the toxin had been
purified over 3,000-fold. Nondenaturing PAGE of the toxin
preparation after this step revealed only one major protein
band that coincided with the peak of cytotoxic activity
eluted from the gel (Fig. 4). The two lightly staining bands
near the cathode were attributed to contaminants in the Tris
buffers, since they appeared in lanes without samples as well
as in lanes containing samples. In later gels (Fig. 5), the
bands disappeared when a new lot of Tris base was used for
the preparation of the gels.
The immunoaffinity column was made with MAb BC5
BB12, which recognized the B subunit of SLT-II (see Fig. 7).
The affinity column step resulted in approximately a 12%
increase in specific activity (Table 1). Since toxin from the
INFECT. IMMUN.






















FIG. 1. Representative anion-exchange (DEAE) column elution profile of approximately 200 mg of total protein of crude SLT-II
(ammonium sulfate precipitate) collected in 3-ml volumes. Fractions 26 to 39, which had a cytotoxic activity greater than 104 CD5Wml, were
pooled.
affinity column could conceivably have been a mixture of
holotoxin and free B subunits, the pure toxin was subjected
to gel filtration chromatography on Bio-Gel P-100 resin.
Fractions were monitored for cytotoxic activity and the
presence of B subunit by SDS-PAGE. No fractions contain-
ing only B subunit were detected (data not shown).
Characterization of SLT-II. When applied to SDS-PAGE,









The most darkly staining band (B subunit) had a molecular
weight of 10,200 + 800. The intensity of staining of this band
indicated that the toxin molecule may be composed of
multiple B subunits. The larger subunit (A subunit) had a
molecular weight of approximately 32,000. A putative A1
subunit was also observed as a lightly staining band with a
molecular weight of approximately 25,000. This band was




















FIG. 2. Representative chromatofocusing column elution profile of 158 mg of total protein of anion-exchange pool concentrate collected













































FIG. 3. Cation-exchange (CM-Sepharose) column elution profile of 22 mg of total protein of chromatofocusing pool concentrate collected
in 3-ml volumes. Fractions 104 to 125, which had a cytotoxic activity greater than 10' CD50ml, were pooled.
Shiga toxin (20). Western blot analysis showed that the A
and the putative A1 subunits were both recognized by
SLT-II specific MAbs DC1 EH5 and GB6 BA4 (see Fig. 7).
Isoelectric focusing gels of affinity-purified SLT-II have
shown one or two bands in the pH range of 5.1 to 5.3.
Isoelectric focusing of the affinity-purified toxin in thin-layer
polyacrylamide gels showed a sharp, intensely staining band
with a PI of 5.2 and fainter bands with pls around 5.1 (Fig.
6). In some purified toxin preparations after electrofocusing
on agarose gels, we observed two sharp bands with pIs of 5.2
and 5.3. Cytotoxicity assays on material eluted from slices of
the agarose gel revealed that virtually all the cytotoxic
activity applied to the gel migrated in the same location as
the protein bands at pH 5.2 and 5.3 (data not shown). The
two bands may represent holotoxin and free B subunit,
which has a predicted pI of 5.38 (10) (processed B subunit).
Alternatively, the two bands may represent heterogeneity in
the holotoxin owing to various numbers of B subunits
associated with the A subunit. Heterogeneity in the holo-
toxin is more likely, since no free B subunit was detected in
that affinity-purified toxin preparation by gel filtration.
The pure toxin was cytotoxic to HeLa cells and Vero cell
monolayers (see Table 3). As little as 1.1 pg of pure toxin
killed 50% of the HeLa cells in the microdilution cytotoxicity
assay (Table 1). SLT-II-specific polyclonal antibodies and
MAbs neutralized the pure toxin, whereas anti-SLT-I MAb
13C4 did not neutralize the toxin (Table 2). Preliminary
experiments with purified SLT-II showed that the toxin was
lethal for mice and rabbits (data not shown).
MAb production. The use of a toxoid of partially purified
toxin as the antigen facilitated the production of five hybrid-
oma cell lines which produced SLT-II neutralizing antibod-
ies (Table 2). All monoclones characterized were of the IgGl
heavy-chain and kappa light-chain classes.
Two monoclones recognized the A and A1 subunits of
Western-blotted toxin proteins, whereas the remaining three
monoclones recognized the B subunit (Fig. 7; Table 3). None
of the five SLT-II-specific antibodies described here bound
to the A or B subunits of Western-blotted crude Shiga toxin.
MAb 13C4 did not bind to the subunits of SLT-II; however,
it did recognize the B subunit of Western-blotted crude Shiga
toxin (data not shown).
DISCUSSION
Using the procedures presented here, we purified SLT-II
to apparent homogeneity. Recently, Padhye et al. (26) and
Yutsudo et al. (35) reported purification schemes for VTs
that are immunologically unrelated to Shiga toxin. Padhye et
al. present a scheme for purifying a unique Vero cytotoxin
TABLE 1. Purification yield of SLT-II from E. coli NM522(pEB1)
Total Total Sp act Fold%Yil
Fraction Vol (ml) cytotoxicity protein (CD50mg) purification % Yield(CD50) (mg)
Bacterial cell lysate 69 2.8 x 108 1,070 2.6 x 105
Ammonium sulfate precipitate 40 2.6 x 108 424 6.1 x 105 2.3 92.8
Anion-exchange pool concentrate 20 1.3 x 108 164 7.9 x 105 3.0 46.4
Chromatofocusing pool concentrate 26 1.0 x 108 22.1 4.5 x 106 17.3 35.7
Cation-exchange pool concentrate 5 8.0 x 107 0.1 8.0 x 108 3,077 28.6
Affinity column pool concentrate 18 7.2 x 107 0.079 9.1 x 108 3,500 25.7
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FIG. 4. Nondenaturing PAGE of SLT-II eluted from the cation-
exchange column. Approximately 30 ,ug of cation-exchange-concen-
trated pool protein was run in each of two lanes of a nondenaturing
polyacrylamide gel. One lane was silver stained, and the other lane
was sliced into 2-mm segments which were passively eluted into 1
ml of PBS. Eluates from each slice were assayed for cytotoxic
activity. The darkly staining bands correspond to the peak of
cytotoxicity.
from culture filtrates by ultrafiltration and anion exchange
chromatography. Yutsudo et al. describe a scheme for
purifying VT2 from culture filtrates by ammonium sulfate
fractionation, DEAE-cellulose chromatography, repeated
chromatofocusing chromatography, and repeated high-per-
formance liquid chromatography (35). Our method differed
from those previously reported in that we purified cell-
associated toxin. We used a scheme similar, in part, to the
Anode
FIG. 6. Silver-stained thin-layer polyacrylamide isoelectric fo-
cusing gel of affinity-purified SLT-II. Lanes: 1, pl standards (FMC
Corp.); 2, approximately 25 ng of affinity-purified SLT-II.
one reported by Yutsudo et al.; however, we differed from
Yutsudo et al. in our use of a single chromatofocusing
chromatography, cation-exchange chromatography, and
monoclonal antitoxin affinity chromatography.
The strain (J-2) used by Yutsudo et al. (35) as a source of
toxin is reported to produce only VT2. Other than the unique
Vero cytotoxin that is not neutralizable with antibodies
against Shiga toxin, Padhye et al. (26) do not comment on
whether other cytotoxins are produced by their strain
(EDL932). Strain EDL932, originally isolated at the Centers
for Disease Control, was included in a study reported by
Marques et al. (15) and was found to produce both SLT-I and
SLT-II. Since only neutralization data with anti-Shiga toxin










FIG. 5. Silver-stained SDS-PAGE analysis of affinity purified
SLT-II. Lanes: 1, 12 ,ug of protein of affinity-purified SLT-II; 2,
low-molecular-mass standards (Sigma). Kd, Kilodaltons.
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FIG. 7. Western blot analysis of affinity-purified SLT-II immu-
nostained with MAb ED5 DF3 (lane A), MAb EA5 BA3 (lane B),
MAb BC5 BB12 (lane C), MAb DC1 EH5 (lane D), or MAb GB6
BA4 (lane E). No reaction of MAb 13C4 specific for the B subunit of
SLT-I with the A and B subunits of SLT-II was observed (data not
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TABLE 2. Antigenic characterization of purified SLT-II
Cytotoxicity Neutralization of cytotoxicity
Toxin HeLa Vero MAb Rabbit MAb BC5 Rabbit
cells cells 13C4 anti-SLT-I BB12a anti-SLT-I1
Pure SLT-II + + - - + +
Pure SLT-Ib + + + +
Shiga toxin (crude)' + + + + +
a Similar results were obtained with MAbs DC1 EH5, EA5 BA3, ED5 DF3, and GB6 BA4.
b SLT-I was purified from E. coli EDL931 as described by O'Brien and LaVeck (22).
c The Shiga toxin preparation was a polymyxin B extract from Shigella dysenteriae type 1 strain 60R.
were reported, it is not clear whether the toxin purified by
Padhye et al. is related to, or the same as, SLT-II or VT2.
The production of a cytotoxin distinct from SLT-I and
SLT-II is possible, since the culture and assay conditions
used for detecting the SLTs may not have been optimal for
other Vero cytotoxins.
There were similarities and differences between the SLT-
II we purified and the VTs reported by Yutsudo et al. (35)
and Padhye et al. (26) Both VT2 purified by Yutsudo et al.
and SLT-II consisted of A and B subunits of similar sizes.
The A and B subunits of SLT-II have molecular weights of
32,000 and 10,200 ± 800, respectively, whereas the A and B
subunits of VT2 have molecular weights of 35,000 and
10,700, respectively. The sizes of the subunits for SLT-II are
also consistent with minicell and DNA sequence data re-
ported for SLT-II (10, 18). From the DNA sequence analysis
of SLT-II, the predicted molecular weights of the mature A
and B subunits were 33,135 and 7,817.
The observed sizes of the B subunits for SLT-II and VT2
were larger than predicted for the mature B subunit from the
nucleotide sequence data. The degree to which the B subunit
is processed for SLT-II or VT2 is not known. Newland et al.
(18) observed no processing of the SLT-II A and B subunits
with polymyxin B treatment of labeled minicells.
In contrast, Padhye et al. (26) report that their toxin does
not consist of subunits. The molecular weight of their toxin
is 64,000 by SDS-PAGE and 54,000 by molecular-sieve
chromatography. Although single bands are evident after
Coomassie blue staining of SDS-polyacrylamide and isoelec-
tric focusing gels, it is not clear from their data that the
cytotoxicity migrated with these protein bands.
SLT-II purified in our study had a pI of 5.2. The pIs
reported by Yutsudo et al. (35) and Padhye et al. (26) are 4.1
and 5.2, respectively. It is not clear why there is such a
difference between our pl and that of Yutsudo et al. One
possible explanation would be that the pls differ owing to the
number of B subunits which are associated with the holo-
TABLE 3. Characterization of SLT-II-specific MAbs
Culture
Hybridoma SLT-II subunit supernatant
cell linea specificity neutralizating
titerb
BC5 BB12 B 640
DC1 EH5 A 40
EA5 BA3 B 80
ED5 DF3 B 320
GB6 BA4 A 80
a The immunoglobulin isotype was immunoglobulin Gl kappa for all cell
lines.
b Reciprocal of the dilution of hybridoma culture supernatant fluid which
neutralized 50 CD50 of crude SLT-II.
toxins from different strains. Heterogeneity in the number of
B subunits associated with the A subunit may also account
for the broad pH range over which SLT-II eluted from the
chromatofocusing column. The pIs of SLT-II and VT2 may
also differ with the source of the toxins (cell associated
versus extracellular) used in the purification schemes. It is
interesting that the toxin of Padhye et al. has the same pI as
SLT-II but does not consist ofA and B subunits. In contrast,
the pIs of Shiga toxin and SLT-I (7.03 + 0.02 [22]) are quite
different from those of SLT-II, VT2, and the unique Vero
cytotoxin.
The biologic activities of SLT-II and the toxins purified by
Yutsudo et al. (35) and Padhye et al. (26) were similar;
however, the specific activities differed. All three toxins
were cytotoxic to either Vero or HeLa cells and lethal for
mice. For both SLT-II and VT2, 1 CD50 unit was approxi-
mately 1 pg; however, for the toxin purified by Padhye et al.,
1 CD50 unit was 25 pg. There was over a 200-fold difference
between the 50% lethal doses of VT2 and the unique Vero
cytotoxin for mice. Yutsudo et al. report that 1 ng of VT2
was a 50% lethal dose (20-g ddY mice, intraperitoneal
injection), whereas Padhye et al. report that 270 ng of unique
Vero cytotoxin was a 50% mouse lethal dose (20-g Sprague-
Dawley mice, intraperitoneal injection) (25). Variation in
specific activities could result from differing amounts of
inactive toxin such as free B or A subunits, varying degrees
of purity, or differing sensitivities of the cell lines or animals.
No cross-neutralization was apparent in reciprocal titra-
tions of Shiga toxin and SLT-II against specific polyclonal
antibodies and MAbs. On the basis of biochemical charac-
teristics such as pI and immunological characteristics in
neutralization experiments, Shiga toxin or SLT-I and SLT-II
were dissimilar. However, biologic similarities between
these toxins may be more important in determining their
relevance in the pathogenicity of a newly recognized group
of enterohemorrhagic E. coli strains (14).
The identification of SLT-producing bacteria by the cell
culture toxicity assay is time-consuming and expensive, and
requires a level of expertise and special facilities not gener-
ally available in clinical or public health microbiology labo-
ratories. The development of rapid, simple assays for these
toxins should facilitate more widespread testing for these
organisms and subsequently lead to a better appreciation of
their prevalence. The purification of SLT-II and the produc-
tion of specific MAbs have provided reagents for the devel-
opment of assays to detect this toxin and antibodies against
it in specimens from patients. Using these reagents, we have
developed an enzyme-linked immunosorbent assay for SLT-
II (F. P. Downes et al., manuscript in preparation). The
purified toxins and monoclones should also facilitate animal
studies of hemorrhagic colitis and HUS and help define the
role of SLTs in these diseases.
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